We are live on ! Find out more
BBC icon

Virtus Biotech Clinical Trials ETF
BBC

15 hedge funds and large institutions have $10.8M invested in Virtus Biotech Clinical Trials ETF in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

9.26% more ownership

Funds ownership: 29.65% → 38.91% (+9.3%)

6% less funds holding

Funds holding: 16 → 15 (-1)

13% less capital invested

Capital invested by funds: $12.4M → $10.8M (-$1.58M)

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
4
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Niemann Capital Management
Nevada
+$1.32M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.1M
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$342K
4
LPL Financial
LPL Financial
California
+$246K
5
Morgan Stanley
Morgan Stanley
New York
+$193K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$1.38M
2
AWCI
Alpine Woods Capital Investors
New York
-$742K
3
Bank of America
Bank of America
North Carolina
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
1
Royal Bank of Canada
Ontario, Canada
$4.36M +$1.1M +31,870 +27%
Goldman Sachs
2
Goldman Sachs
New York
$2.93M – – –
NCM
3
Niemann Capital Management
Nevada
$1.12M +$1.32M +38,228 New
LPL Financial
4
LPL Financial
California
$857K +$246K +7,126 +32%
Morgan Stanley
5
Morgan Stanley
New York
$556K +$193K +5,602 +42%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$389K +$24.2K +703 +6%
Envestnet Asset Management
7
Envestnet Asset Management
Illinois
$291K +$342K +9,925 New
Osaic Holdings
8
Osaic Holdings
Arizona
$253K +$297K +8,621 New
US Bancorp
9
US Bancorp
Minnesota
$29K – – –
UBS Group
10
UBS Group
Switzerland
$26K +$31.1K +903 New
Wells Fargo
11
Wells Fargo
California
$7K – – –
ASN
12
Advisory Services Network
Georgia
$7K +$8.72K +253 New
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.22K – – –
OPS
14
Orion Portfolio Solutions
Nebraska
$2K +$2.07K +60 New
FCM
15
Firestone Capital Management
Florida
$1K – – –
Jane Street
16
Jane Street
New York
– -$1.38M -36,323 Closed
AWCI
17
Alpine Woods Capital Investors
New York
– -$742K -19,500 Closed
Bank of America
18
Bank of America
North Carolina
– -$5K -126 Closed

BBC Hedge Fund Activity: Q1 2020 in Review

15 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2020, worth a combined $10.8M — down 13% from $12.4M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BBC positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Niemann Capital Management, opening a new position worth an estimated $1.32M. The largest seller was Jane Street, exiting entirely with an estimated $1.38M sold.

  • 15 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2020, down from 16 in Q4 2019.
  • Funds reported $10.8M of Virtus Biotech Clinical Trials ETF stock for Q1 2020, down 13% quarter-over-quarter.
  • 6 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2020 and 3 closed out, a net change of +3 holders.
  • The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2020 was Niemann Capital Management, an estimated $1.32M added.
  • The largest Virtus Biotech Clinical Trials ETF seller in Q1 2020 was Jane Street, an estimated $1.38M sold.

Based on aggregated 13F filings for Q1 2020.